Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer
JCO Precision Oncology · 2024
DOI: 10.1200/po.23.00330 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Emmanuel S Antonarakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota Masonic Cancer Center, Minneapolis, MN. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Mutation, Receptors, Androgen, Circulating Tumor DNA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) is typically treated with agents directly or indirectly targeting the androgen receptor (AR) pathway. However, such treatment is limited by resistance mechanisms, including the development of activating mutations in the AR ligand-binding domain ( AR-LBD). METHODS This study evaluated a database of over 15,000 patients with advanced prostate cancer (PC) undergoing comprehensive circulating-tumor DNA analysis (Guardant360, Redwood City, CA) between 2014 and 2021, with associated clinical information from administrative claims (GuardantINFORM database). RESULTS Of 15,705 patients with PC included, 54% had mCRPC at the time of their blood draw. Of those, 49% had previous treatment with an AR pathway inhibitor (ARPi). AR-LBD mutation prevalence was 15% in patients with mCRPC who were untreated with a next-generation ARPi, 22% in those after one line of ARPi therapy, and 24% in those after two lines of ARPi treatment. Next-generation ARPi treatment yielded an increase in AR L702H and T878A/S mutations after abiraterone, and an increase in AR L702H and F877L mutations after enzalutamide. AR-LBD+ patients demonstrated unique biology, including increased concurrent mutations in the cell-cycle, wingless-related integration site, homologous recombination repair, and phospho-inositide 3-kinase pathways (all P < .0005), and greater low-level (copy number
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Minnesota Masonic Cancer Center, Minneapolis, MN.
- Guardant Health, Palo Alto, CA.
- Orion Corporation, Orion Pharma, Espoo, Finland.
- Orion Pharma, Nottingham, United Kingdom.
- Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
ORCID-Profile: Emmanuel S Antonarakis, L Jill Tsai, Chris Garratt, Karim Fizazi
Förderung
- NCI NIH HHS
Zitieren
APA
Antonarakis, E. S., Zhang, N., Saha, J., Nevalaita, L., Ikonen, T., Tsai, L. J., Garratt, C., & Fizazi, K. (2024). Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00330
Vancouver
Antonarakis ES, Zhang N, Saha J, Nevalaita L, Ikonen T, Tsai LJ, et al. Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00330
BibTeX
@article{Antonarakis2024,
author = {Antonarakis, Emmanuel S and Zhang, Nicole and Saha, Jayati and Nevalaita, Liina and Ikonen, Tarja and Tsai, L Jill and Garratt, Chris and Fizazi, Karim},
title = {Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.23.00330}
}
EUVIMED